HighVista Strategies’s Neurogene NGNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-3,562
Closed -$877K 131
2021
Q1
$877K Buy
3,562
+76
+2% +$19.4K 0.65% 23
2020
Q4
$983K Buy
3,486
+1,524
+78% +$372K 0.63% 28
2020
Q3
$471K Buy
1,962
+534
+37% +$129K 0.34% 56
2020
Q2
$474K Buy
+1,428
New +$372K 0.39% 29

Other funds holding NGNE

HighVista Strategies's NGNE Position: Q2 2021 in Review

HighVista Strategies sold out of Neurogene (NGNE) in Q2 2021, closing a stake of 3,562 shares — an estimated $877K sold.

HighVista Strategies first reported a position in NGNE in Q2 2020 and held it in 4 quarters. The position peaked at $983K in Q4 2020. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2021.

  • HighVista Strategies reported no remaining Neurogene position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 3,562 Neurogene shares in Q2 2021, an estimated $877K.
  • HighVista Strategies first reported a position in Neurogene in Q2 2020 and held it in 4 quarters.
  • HighVista Strategies's Neurogene position peaked at $983K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.